A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Massachusetts General Hospital
Seagen Inc.
Seagen Inc.
Beth Israel Deaconess Medical Center
MOMA Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cedars-Sinai Medical Center
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
AstraZeneca
Taiho Oncology, Inc.
Revolution Medicines, Inc.
Queen Mary University of London
Actuate Therapeutics Inc.
University of Arizona
University of Oklahoma
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
NYU Langone Health
University Medical Centre Ljubljana
Washington University School of Medicine
City of Hope Medical Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
CHU de Quebec-Universite Laval
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Astellas Pharma Inc
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
M.D. Anderson Cancer Center
Hoffmann-La Roche
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University Hospital, Antwerp
University of California, Davis
Erasca, Inc.